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Abstract
Flap endonuclease 1 (FEN1) is a structure selective endonuclease required for proficient
DNA replication and the repair of DNA damage. Cellularly active inhibitors of this enzyme
have previously been shown to induce a DNA damage response and, ultimately, cell death.
High-throughput screens of human cancer cell-lines identify colorectal and gastric cell-lines
with microsatellite instability (MSI) as enriched for cellular sensitivity to N-hydroxyurea
series inhibitors of FEN1, but not the PARP inhibitor olaparib or other inhibitors of the DNA
damage response. This sensitivity is due to a synthetic lethal interaction between FEN1 and
MRE11A, which is often mutated in MSI cancers through instabilities at a poly(T) microsatel-
lite repeat. Disruption of ATM is similarly synthetic lethal with FEN1 inhibition, suggesting
that disruption of FEN1 function leads to the accumulation of DNA double-strand breaks.
These are likely a result of the accumulation of aberrant replication forks, that accumulate
as a consequence of a failure in Okazaki fragment maturation, as inhibition of FEN1 is toxic
in cells disrupted for the Fanconi anemia pathway and post-replication repair. Furthermore,
RAD51 foci accumulate as a consequence of FEN1 inhibition and the toxicity of FEN1 inhibi-
tors increases in cells disrupted for the homologous recombination pathway, suggesting a
role for homologous recombination in the resolution of damage induced by FEN1 inhibition.
Finally, FEN1 appears to be required for the repair of damage induced by olaparib and cis-
platin within the Fanconi anemia pathway, and may play a role in the repair of damage asso-
ciated with its own disruption.
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Introduction
Flap endonuclease 1 (FEN1) is a structure-specific endonuclease and prototypical member of
the RAD2-superfamily [1–3], required for the removal of 5’ flaps that arise as a consequence of
Okazaki fragment displacement by replicative polymerases during lagging strand synthesis [4,
5]. This process is critical for proficient and processive replication, with many cancer cells
showing over-expression of FEN1 [6–9]. Haploinsufficiency of FEN1 is associated with abnor-
mal cell-cycle progression and cancer predisposition with decreased survival, driven by an
accumulation of replication-associated alterations in DNA, such as microsatellite instabilities
(MSI) and tri-nucleotide repeat expansion [10–12]. FEN1 also plays a role in the maintenance
of telomeres in the absence of telomerase [13], the processing of stalled replication forks [14,
15], and in a number of DNA damage repair processes, including base excision repair (BER)
[16], alternative end-joining (alt-EJ) [17] and homologous recombination (HR) [18]. As a
result, cells defective for FEN1 activity are sensitive to many DNA lesions [15, 19–24] and,
therefore, FEN1 is an attractive target for drug discovery.
Previously it has been shown that the N-hydroxyurea series small molecule 1-(2,3-dihydro-
1,4-benzodioxin-2-ylmethyl)-3-hydroxythieno[2,3-e]pyrimidine-2,4-dione (compound 1; Fig
1) can inhibit FEN1 activity in vitro [25, 26]. We have shown that compound 1 co-crystallizes
within the active site of FEN1 in vitro, with inhibition achieved partly through the co-ordina-
tion of Mg2+ ions by the N-hydroxyurea moiety of 1 (shaded purple in Fig 1) [25]. These metal
ions are critical for base un-pairing; the disruption of base pairing within the substrate, close
to the junction of single-strand to double-strand DNA, which induces an essential conforma-
tional change within the substrate duplex to allow for enzymatic cleavage [2, 27]. Further, the
thiophene ring of 1 (shaded blue in Fig 1) sits within a hydrophobic pocket of FEN1 contain-
ing conserved active site residues Y40, D181 and R100 essential for substrate positioning [2,
27, 28]. Binding of 1 to the active site occurs in both a competitive and non-competitive man-
ner with DNA, and, potentially, induces a dominant negative effect, with a FEN1-inhibitor
‘dead-end’ complex associating into replication and repair complexes, such as the
PCNA-Pol@-FEN1 complex that stimulates Okazaki fragment maturation [29, 30]. Further
members of this N-hydroxyurea series (compounds 2–3; Fig 1) have similarly been shown to
inhibit FEN1 activity in biochemical assays [31]. This inhibitory activity is largely competitive
with substrate, suggesting a different mode of action to 1 [25]. In the present study, we investi-
gate further the therapeutic potential of N-hydroxyurea series inhibitors of FEN1.
Disruption or inhibition of FEN1 in both higher and lower eukaryotes induces a DNA
damage response. Saccharomyces cerevisiae cells deficient for the FEN1 homologue RAD27 dis-
play temperature-dependent hyper-activation of post-replication repair (PRR) and DNA dou-
ble-strand break (DSB) repair pathways following accumulation of unprocessed Okazaki
fragments [19, 32, 33]. Previously [25] we demonstrated that N-hydroxyurea series molecules
bind FEN1 protein ex vivo and that this binding translates to cellular activity, with mammalian
cells treated with 1 initiating a DNA damage response in a dose-dependent manner. Similarly,
we demonstrated that FEN1 inhibition activated the ATM checkpoint signalling pathway, the
phosphorylation of histone H2AX and the ubiquitination of FANCD2 [25], suggesting the ini-
tiation of the Fanconi anemia (FA) pathway. The FA pathway is required for the stabilisation
of stalled replication forks (Fig 2) and these data suggest that 1 induces replication-associated
DNA damage. Moreover, it has been shown that inhibition of FEN1 is synthetic lethal with
deficiencies in MRE11A [34], a member of the MRN (MRE11A-RAD50-NBS1) complex
required for the sensing of DSBs and the activation of cell-cycle checkpoints (Fig 2) [35–38].
Following the sensing of DSBs by the MRN complex the kinases ATM and ATR induce DNA
damage checkpoint signalling and repair is conducted via two main pathways: HR and non-
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homologous end-joining (NHEJ) (Fig 2). Previous data has suggested that mutation of FEN1
in Saccharomyces cerevisiae and humans is synthetically lethal with HR factors [32, 39–41]. In
the current study, we further investigate the activity of N-hydroxyurea series inhibitors of
FEN1 in human cancer cells by high-throughput and targeted means. We identify synthetic
genetic interactions between these inhibitors and disruption of DNA damage repair genes,
and our data suggests FEN1 as a potential target for drug discovery in DNA repair-deficient
cancers.
Fig 1. Chemical structure of N-hydroxyurea series inhibitors of FEN1 used in this study.
https://doi.org/10.1371/journal.pone.0179278.g001
Fig 2. Model for the repair of DNA double-strand breaks. DSBs are recognised by the MRN complex (i.) which binds to the blunt
DNA ends, holding them in close proximity. The exonuclease activity of MRE11A (or EXO1 in concert with BLM) is able to resect blunt
ends, creating a 3’ ssDNA overhang, which becomes coated by the single-strand binding protein RPA (ii.), signalling for cell-cycle
checkpoint arrest via ATR. RPA is displaced by RAD51 (iii.) to allow for HR. Alternatively, the MRN complex can be replaced by KU78/
KU80 complex (iv.), protecting DNA ends from resection and promoting NHEJ through the binding of the DNA-PK catalytic subunit
(DNA-PKcs). DSBs formed as a consequence of replication fork collapse require HR for their repair. Fork stalling, following replication
stress for example, activates the FA pathway in an attempt to stabilise and protect the fork (v.). The FA core complex recognises the
stalled fork and ubiquitinates the FANCD2-FANCI heterodimer. Stalled forks can be further processed by structure selective
endonucleases to restore the replication fork (vi.) or cleave the fork to produce a DSB (vii.). Alternatively, the post-replication machinery
can bypass damaged bases at stalled forks. One such pathway leads to template switching in a HR-mediated pathway.
https://doi.org/10.1371/journal.pone.0179278.g002
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Results and discussion
A high-throughput screen identifies potential cancer sub-populations
sensitive to chemical inhibitors of FEN1
Previously we have shown that chemical inhibition of FEN1 leads to DNA damage accumula-
tion and ultimately cell death. We wanted to further examine the cytotoxic efficacy of FEN1
inhibition, to determine whether there was any tissue or genetic influence on those cells sensi-
tive to treatment with these compounds. Initially, we conducted high-throughput screens
across a panel of 280 cancer cell-lines derived from solid tumours from a number of tissue
types. We continuously dosed each cell-line with 0–30 μM of three previously identified FEN1
inhibitors (compounds 1–3) from the N-hydroxyurea series for 3 days and measured their
growth inhibition effect (Table 1, S1 Table and Fig 3A). Dose-response results were obtained
from 212 cell-lines treated with 1 with a mean GI50 of 15.5 μM. We were unable to calculate
GI50 values for 26 of these cell-lines within the dose-range tested (i.e. the GI50 was greater than
30 μM), and these cell lines were deemed to be ‘resistant’ by this assay. N-hydroxyurea series
compounds 2–3 similarly are inhibitors of FEN1 shown to have activity in biochemical assays
[25, 26, 31]. FEN1 binding and inhibition by these molecules fit a competitive model while
compound 1 fits a mixed non-competitive/competitive model, binding to FEN1 either in the
presence or absence of DNA substrate [25]. We see little cellular activity for 2 in our high-
throughput screen, with 79% cell-lines showing resistance to treatment with the dose-range
specified. 3 is a structural relative of 2, replacing a cyclopropylmethyl side-chain with a longer
4-methoxyphenyl. This modification enhanced cellular activity with a mean GI50 of 9.0 μM in
the 195 cell-lines for which data was obtained, and 30 cell-lines (15%) showing resistance (Fig
3A). There was good Pearson’s correlation (ρ = 0.86) between sensitivity to 1 and 3 (Fig 3B),
suggesting that cellular activity is likely due to the common inhibition of FEN1 despite the dif-
fering modes of inhibition.
We wanted to determine whether there was any tissue-type specificity to FEN1 inhibitor
sensitivity. We therefore split the cell-lines into broad panels by tissue of origin and compared
GI50 (Tables 2–4 and S1–S3 Figs). While cell-lines derived from head and neck cancers appear
to be more resistant to treatment with 3 than other panels, there was otherwise very little dif-
ference between the mean GI50 across the tissue-types with any of the compounds tested. Sub-
sequently, we further separated the cell-lines according to known cancer sub-types, with no
significant difference in the mean GI50 of these cancer sub-types for any of the compounds
tested (see S1–S3 Figs). Next we examined the sensitivity in cell-lines with mutations in genes
associated with cancer (KRAS, p53 and PTEN), again with no significant difference in sensitiv-
ity to FEN1 inhibition for all compounds tested (see S1–S3 Figs). Finally, we compared cell-
lines with known MSI with cells shown to have stable microsatellites (MSS) from the same tis-
sue-type (Table 5). MSI is a form of genetic hypermutability associated with variations in poly-
nucleotide tracts. Approximately 10–15% of colorectal cancers (CRC) and ovarian cancers
Table 1. Summary of a high-throughput study to identify cell-lines sensitive to FEN1 inhibitors.
Compound 1 2 3
Cell-lines screened 212 180 195
Resistant cell-linesa 26 (12%) 143 (79%) 30 (15%)
Geometric mean 15.5 27.3 9.0
95% Confidence interval 1.0 0.7 1.2
a Resistance was defined as GI50 greater than the maximum dose used in this study (30 μM).
https://doi.org/10.1371/journal.pone.0179278.t001
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Fig 3. Cell-lines with MSI are specifically sensitive to chemical inhibition of FEN1 by compounds 1
and 3. A. Box and whisker diagram to show the variation in GI50 values for cell-lines subject to treatment with
1 and 3. B. Correlation between the sensitivity of cell-lines to 1 and 3. C-H. The influence of MSI on sensitivity
to DNA repair inhibitors. ns = not significant * p < 0.05. ** p < 0.005.
https://doi.org/10.1371/journal.pone.0179278.g003
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display MSI associated with a failure in genome surveillance by the mismatch repair (MMR)
machinery, while MSI is also evident in head and neck, lung, oesophageal, pancreatic and
prostate cancers [42–45]. Waterfall plots suggest that cell-lines with MSI were, largely, more
sensitive to treatment with 1 and 3, falling below the mean GI50 for all cell-lines tested (green
bars, panel H in S1 Fig and panel H in S3 Fig) and showed a statistically significant increase in
sensitivity compared with MSS cell-lines (Fig 3C and 3D). These data suggest MSI as a poten-
tial cancer subset with selective sensitivity to FEN1 inhibition. We considered that this effect
may be through the inhibition of BER, a DNA repair pathway in which FEN1 plays a role. We
therefore screened MSI and MSS cell-lines against another BER inhibitor, the cellular active
DNA Polymerase β inhibitor NSC666715 [46, 47] (Fig 3E). No significant difference between
the two cell populations was seen. Similarly, we screened these cell panels for sensitivity to
inhibitors of other DNA damage response elements, including the ATR inhibitor AZD6738
[48], ATM inhibitor KU-55933 [49] or PARP inhibitor olaparib [50] (Fig 3F–3H). No signifi-
cant difference in sensitivity to these inhibitors was seen between the two populations. These
data would suggest that toxicity of compounds 1–3 in MSI cells is specific and not due to an
addiction to the DNA damage response more generally.
Colorectal cancer cell-lines with microsatellite instability-induced
MRE11A deficiency are sensitised to down-regulation of FEN1
DNA repair genes are frequently co-mutated with MMR due to polymorphisms at microsatel-
lites resulting from an accumulation of replication errors. MRE11A for example is commonly
mutated at a microsatellite comprising a tract of 11 thymine residues (poly(T)11 microsatellite)
in intron 4 [51–54]. Previously, MRE11A has been shown to be synthetic lethal with FEN1 [33,
35] and we therefore wanted to investigate the possibility that the selective sensitivity of FEN1
inhibitors is due to a loss of MRE11A. Of the seven confirmed MSI cell-lines examined in our
high-throughput screen, five have been shown to have deleterious poly(T)11 mutations in one
or more alleles of MRE11A (Table 5). We examined the role of MRE11A in the tolerance of 1
by initially treating cells stably expressing shRNA against MRE11Awith the compound and
compared sensitivity to an isogenic control cell-line expressing a non-targeting shRNA (Fig
4A). Cells disrupted for MRE11Awere more sensitive to a dose escalation of 1, and at 10 μM 1
we saw 11% survival in the MRE11A deficient cell-line compared to 66% in the control cell-
line.
Table 2. Tissue-specific sensitivity to compound 1. a Resistance was defined as GI50 greater than the maximum dose used in this study (30 μM).
Compound 1 Bladder Breast Colorectal Gastric Liver Lung Pancreatic Prostate Gynae Head & Neck
Cell-lines screened 19 22 21 25 21 37 24 7 21 15
Resistant cell-linesa 0 (0%) 2 (9%) 4 (19%) 5 (20%) 3 (14%) 2 (5%) 3 (13%) 0 (0%) 7 (33%) 0 (0%)
Geometric meanb 13.6 13.1 16.7 15.0 20.1 12.1 16.5 17.1 23.1 20.0
95% Confidence interval 2.8 3.0 3.8 3.5 2.7 2.1 2.8 3.6 2.5 2.6
https://doi.org/10.1371/journal.pone.0179278.t002
Table 3. Tissue-specific sensitivity to compound 2. a Resistance was defined as GI50 greater than the maximum dose used in this study (30 μM).
Compound 2 Bladder Breast Colorectal Gastric Liver Lung Pancreatic Prostate Gynae
Cell-lines screened 19 22 21 25 21 40 24 7 1
Resistant cell-linesa 18 (95%) 14 (64%) 15 (71%) 17 (68%) 19 (90%) 32 (80%) 21 (88%) 6 (86%) 1 (100%)
Geometric meanb 29.0 27.6 28.9 26.9 29.6 28.9 28.8 29.3
95% Confidence interval 1.5 1.4 0.9 1.8 0.5 0.8 1.2 1.2
https://doi.org/10.1371/journal.pone.0179278.t003
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Next, we wanted to examine further whether inhibition of FEN1 was responsible for lethal-
ity in MRE11A deficient MSI cells. We constructed a mini-panel of colorectal cancer cell-lines
that differ by MSI-status and the mutation status of the MRE11A poly(T)11 microsatellite (Fig
4B), subject them to siRNA against FEN1 and scored for clonogenic survival (Fig 4C) or ability
to proliferate (Fig 4D–4F). SW620, an MSS cell-line [55], MRE11A expressing cell-line showed
no sensitivity to FEN1 disruption (Fig 4C & 4D). DLD-1 cells have MSI [55], yet these cells
retain MRE11A protein as only one MRE11A poly(T)11 allele is mutated. Again, these cells are
insensitive to FEN1 siRNA treatment (Fig 4C). HCT-116 cells are similarly MSI [56], however,
mutation of both MRE11A poly(T)11 alleles means this cell-line is devoid of MRE11A protein
(Fig 4B). These cells are sensitive to FEN1 siRNA treatment (Fig 4C & 4E), suggesting that
Table 5. MRE11A poly(T)11 mutations associated with MSI.
Cell-Line MSI Status MMR Defect MRE11A poly(T)11 Intron 4 1
HCT 116 MSI-H MLH1 T10/T9
HCT-15/DLD-1 MSI-H MSH6 T11/T9
LoVo MSI-H MSH2 T10/T10
RKO MSI-H MLH1 T10/T9/T8
SW48 MSI-H MLH1 T10/T10
SNU-1 MSI-H MLH1 -
SNU-638 MSI-H MLH1 -
COLO 205 MSS None T11/T11
COLO 320DM MSS None -
HT-29/WiDr MSS None T11/T11
SK-CO-1 MSS None -
SW403 MSS None T11/T11
SW480 MSS None T11/T11
SW620 MSS None T11/T11
SW948 MSS None -
SNU-16 MSS None -
SNU-216 MSS None -
SNU-484 MSS None -
SNU-5 MSS None -
SNU-601 MSS None -
SNU-620 MSS None -
SNU-668 MSS None -
HCT116 CHR3 MSS None2 T10/T9
1 Gene mutations taken from published data if known [51–53].
2 MLH1 is restored by the introduction of wild-type chromosome 3 and has been shown to be mismatch
repair proficient.
https://doi.org/10.1371/journal.pone.0179278.t005
Table 4. Tissue-specific sensitivity to compound 3. a Resistance was defined as GI50 greater than the maximum dose used in this study (30 μM).
Compound 3 Bladder Breast Colorectal Gastric Liver Lung Pancreatic Prostate Gynae Head & Neck
Cell-lines screened 19 22 21 25 21 40 24 7 1 15
Resistant cell-linesa 1 (5%) 1 (5%) 5 (24%) 6 (24%) 4 (19%) 2 (5%) 2 (8%) 0 (0%) 0 (0%) 9 (60%)
Geometric meanb 8.2 6.4 11.0 11.5 11.0 7.4 8.1 9.2 5.2 19.8
95% Confidence interval 2.9 2.6 4.6 4.2 3.8 2.0 3.2 3.0 4.9
https://doi.org/10.1371/journal.pone.0179278.t004
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disruption of FEN1 function by 1 is responsible for toxicity in this cell line. To examine the
role played by MMR in sensitivity to FEN1 disruption, we also examined HCT-116 cells with
chromosome 3 re-introduced, restoring MLH1. This has been shown to restore MMR function
in these cells [57], without affecting MRE11A levels (Fig 4B). Both MMR-deficient and MMR-
proficient cells were similarly sensitive to siRNA against FEN1 (Fig 4C & 4F), suggesting that
the toxicity is specific MRE11A defects and not MMR.
Our previous data suggested that 1 inhibits both FEN1 and EXO1 function in vitro but we
were unable to determine whether this corresponded with cellular activity [26]. In an attempt
to determine whether disruption of EXO1 had an effect on the survival of MRE11A-deficient
MSI cells, we also knocked-down EXO1 in SW620 and HCT-116 cells and examined clono-
genic potential. In both cases, disruption of EXO1 had little effect on viability when compared
to a non-target control (panel A in S4 Fig). Finally, we wanted to examine whether the disrup-
tion of EXO1 played a role in sensitivity to 1, explaining the severe and non-specific toxicity of
1 at high doses [26], we down-regulated EXO1 by siRNA and subject the cells to increasing
Fig 4. Sensitivity of MSI cell-lines to FEN1 inhibition is through MRE11A deficiency. A. Cells down-regulated for MRE11A by shRNA are
sensitive to FEN1 inhibitor 1. B. Confirmation that the MSI cell-line HCT-116 is disrupted for the MRN complex. Re-introduction of chromosome 3
(HCT-116 chr3) restores MLH1 without affecting MRE11A protein level. C-F. Down-regulation of FEN1 by siRNA is toxic in MSI cells devoid of MRN
complex by clonogenic survival (C) or by measuring proliferation (D-F). Each data point is the mean of at least 3 individual repeats and the error
bars represent the standard error. Significance was determined by student t-test. ns = not significant * p < 0.05. ** p < 0.005 G. HCT-116 cells fail to
signal for the DNA damage response upon treatment with 1.
https://doi.org/10.1371/journal.pone.0179278.g004
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concentrations of 1 (panel B in S4 Fig). We find that cells disrupted for EXO1 are no more sen-
sitive to cells treated with a non-target control. This would suggest that the cytotoxicity
induced by 1 is unlikely to be due to inhibition of EXO1 activity.
Finally, we wanted to examine the induction of DNA damage signalling pathways in these
cells. Previously we have shown that treatment with 1 induces a DNA damage response [26].
In cells devoid of MRE11A, this signal is lost, with HCT-116 cells failing to accumulate γH2AX
or activated ATM following treatment with 1 or olaparib (Fig 4G), suggesting that MRE11A is
required for the activation of signalling pathways induced by damage associated with FEN1 or
PARP inhibition.
Cells devoid of the DNA double-strand break sensing machinery are
sensitive to chemical inhibition of FEN1
The MRN complex recognises DSBs and forms part of the signalling cascade that leads to dam-
age induced cell-cycle arrest (Fig 2). This signalling cascade involves the activation of the
kinase ATM by MRN [58]. ATM is activated when FEN1 is inhibited [26] and we hypothesised
that cells deficient for ATM would likely be sensitive to 1. Moreover, while the majority of MSI
cell-lines identified above as sensitive to 1 are mutated for MRE11A, two have mutations in
exon 6 of ATM resulting in a 22 bp deletion in exon 6 (SNU-1 and SNU-638) [59]. When we
examined cells expressing shRNA against ATM for sensitivity to 1, we found that the down-
regulation of ATM lead to a potentiation of the toxic effects of FEN1 inhibition, phenocopying
cells disrupted for MRE11A (Fig 5A). We further examined sensitivity in FaDu cells with all
copies of ATM knocked out using the transcription activator-like effector nuclease (TALEN)
system [60] with compound 1. These cells also displayed greater toxicity than their parental
cell-line (Fig 5B). Similarly, knock-down of FEN1 by siRNA was toxic in these cells (Fig 5C),
suggesting specificity in the activity of 1 in ATM deficient cells, further confirming synthetic
lethality between FEN1 and ATM.
Above we have shown that disruption of the MRN complex leads to both a loss in the acti-
vation of ATM and the accumulation of γH2AX. We examined 1-induced γH2AX accumula-
tion in cells disrupted for ATM by shRNA and found that, in contrast to MRE11A disruption,
γH2AX accumulated more readily in ATM disrupted cells (Fig 5D). These data would suggest
that the MRN complex activates ATM in response to FEN1 inhibition but ATM is not required
for H2AX phosphorylation in this situation.
A role for replication-coupled repair pathways in the tolerance of FEN1
inhibition
The MRN-ATM pathway has a role in the repair of DSBs repaired by NHEJ and canonical HR,
such as those described in Fig 2i.–iv., and it is possible that the activation of this pathway in
cells inhibited for FEN1 is due to an accumulation of such DNA breaks. However, this pathway
has similarly been shown to be activated following the accumulation of more complex DNA
secondary structures, such as stalled replication forks [61] and has been shown to promote rep-
lication restart following the collapse of the stalled forks into DSBs [62, 63]. Stalled replication
forks are recognised by members of the FA pathway, which bind and stabilise the fork while
co-ordinating downstream repair processes through monoubiquitinated FANCD2 (FANC-
D2-Ub) (Fig 2) [64–70]. An accumulation of ubiquitinated FANCD2 is therefore used as a
marker for replication fork instability. Inhibition of FEN1, by treating with compound 1 or
shRNA against FEN1, leads to an increase in FANCD2 mono-ubiquitination (FANCD2-Ub;
panel F in S4 Fig and [26]), suggesting that inhibition of FEN1 leads to the accumulation of
unstable replication forks. We hypothesised therefore that disruption of the FA pathway
Synthetic genetic interactions of FEN1 with DNA damage response genes
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Fig 5. Cells disrupted for pathways required to maintain replication fork stability are sensitive to inhibition of FEN1. A. Clonogenic survival of
cells stably expressing shRNA against MRE11A, ATM or a non-targeting control when treated with 1. B. Clonogenic survival of FaDu cells or FaDu cells
with all three ATM alleles knocked-out when treated with 1. C. Clonogenic survival of FaDu cells or FaDu cells with all three ATM alleles knocked-out
when treated with siRNA against FEN1. D. DNA damage response induced in cells expressing shRNA against FEN1, ATM BRCA2, FANCD2 and a non-
target control. E-F. Clonogenic survival of cells disrupted for FANCD2 by shRNA (E) or genes required for PRR (UBC13, HLTF) by siRNA (F) compared
to a non-target control. (G) Accumulation of Rad51 foci in cells treated with 1. Data is collected from at least 500 cells per treatment. H. Clonogenic
survival of cells disrupted for genes required for HR (BRCA2, BLM) and NHEJ (DNA-PKcs) by shRNA compared to a non-target control. In each
clonogenic assay, data points represent the mean of at least 3 individual repeats and the error bars represent the standard error. Significance was
Synthetic genetic interactions of FEN1 with DNA damage response genes
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would lead to increased sensitivity to 1. We obtained cells downregulated for FANCD2 by
shRNA and treated them with increasing doses of 1. We find that, not only are these cells sen-
sitive to 1, this sensitivity is far greater than in any other cell-line examined (Fig 5E). At 10 μM
1, 1% of FANCD2 deficient cells survive compared with 66% in non-target control cells and
approximately 10% in cells disrupted for MRE11A or ATM. Moreover, these cells accumulate
DNA damage markers far more readily than in cells devoid of ATM (Fig 5D), suggesting that
failure to stabilise stalled replication forks leads to increased DNA damage associate with 1
treatment. These data suggest that chemical inhibition of FEN1 leads to replication fork insta-
bilities that, if left unrepaired, can lead to cell death.
In lower eukaryotes, disruption of RAD27/FEN1 is synthetic lethal with disruption of the
post-replication repair (PRR) damage tolerance pathway [34, 71]. PRR is required to overcome
physical replication blocks or nicks in the DNA and is activated by regions of ssDNA (Fig 2)
[72]. In the absence of RA27, PRR is required to prevent trinucleotide repeat expansion [73],
which is often associated with FEN1 haploinsufficiency in vertebrates [13]. It has previously
been demonstrated that ubiquitination of PCNA occurs following RAD27 inactivation, a phe-
notype supressed by overexpression of EXO1 [34]. Inactivation of RAD27/FEN1 leads to an
increase in length of 5’ flaps formed by replicative polymerases dissociating Okazaki fragments
[74]. These longer flaps become coated in RPA and it has been postulated that these longer
RPA-bound flaps signal for PRR [34]. Furthermore, disruption of RAD27 leads to an accumu-
lation of un-ligated single-strand nicks at Okazaki fragment [20, 33], which may also signal for
PRR during subsequent rounds of replication. We wanted to examine this in our mammalian
system so disrupted UBC13 and the Rad5 homologue HLTF [75], which are PRR factors
required for HR-mediated template switching [76–78], by siRNA and exposed cells to 1. We
found that disruption of either gene led to increased sensitivity to 1, phenocopying the knock-
down of MRE11A by the same method (Fig 5F). It is possible, therefore, that inhibition of
FEN1 by this method leads to an accumulation of aberrant DNA replication structures on the
lagging strand that engages PRR pathway for repair. In the absence of PRR, persistent replica-
tion fork instability ultimately results in cell death.
A role for homologous recombination proteins in the repair of damage
induced by FEN1 inhibition
Disruption of RAD27 in lower eukaryotes is synthetically lethal with disruption of the HR
pathway [32,39–40,79–80]. Since we have shown that inhibition of FEN1 largely recapitulates
the phenotype seen in a yeast rad27 cell, we wanted to examine the role played by HR factors
in the tolerance of chemical inhibition of FEN1. HR is primed by the resection of DNA ends
by MRE11A, resulting in a 3’ ssDNA overhang that rapidly becomes coated in RPA (Fig 2).
RPA is displaced by RAD51 to form protein-DNA filaments that promote recombination. To
determine whether HR is activated by 1, we examined the accumulation of RAD51 foci post
treatment, using the CellInsight high-content screening platform to count all cells containing
defined RAD51 foci within the nucleus. We find that there is a dose-dependent increase in
RAD51 foci following treatment with compound 1 (Fig 5G). The resulting foci are large, form-
ing as a consequence of dynamic nuclear reorganisation post DNA damage [81, 82]. These foci
are entirely nuclear (examples are shown in panel C of S4 Fig), however it is possible that they
are foci prepared for sequestration to micronuclei, suggesting irreparable DNA damage [83].
determined by Student t-test. ns = not significant * p < 0.05. ** p < 0.005 D. DNA damage response induced in cells expressing shRNA against FEN1,
ATM and a non-target control.
https://doi.org/10.1371/journal.pone.0179278.g005
Synthetic genetic interactions of FEN1 with DNA damage response genes
PLOS ONE | https://doi.org/10.1371/journal.pone.0179278 June 19, 2017 11 / 25
This dose-dependent increase coincided with an accumulation of γH2AX foci (panel D of S4
Fig). Furthermore, when cells disrupted for BRCA2 (which is required, among other DNA
repair processes, for canonical HR) by shRNA were subject to increasing concentrations of 1,
we found increased sensitivity that phenocopied MRE11A and ATM disruption (Fig 5H). Dis-
ruption of BRCA2, however, did not increase γH2AX accumulation (Fig 5D), suggesting a role
for BRCA2 downstream of MRE11A. Cells disrupted for DNA-PKcs, a gene required for the
non-homologous end-joining (NHEJ)–a pathway utilised frequently for the repair of simple
DSBs that supresses HR (see also Fig 2)–were no more sensitive to 1 than a non-target control.
Above we have shown that disruption of DNA damage repair proteins contributes to cellu-
lar sensitivity to FEN1 inhibition. We therefore re-examined our high-throughput cell killing
data set to determine whether gene expression and copy number influence sensitivity to our
compounds. We found that cellular sensitivity to N-hydroxyurea series compounds did not
correlate with expression of FANCD2, MRE11A,ATM or BRCA2 with any statistical signifi-
cance (S6 Fig).
FEN1 is epistatic with FANCD2 for the repair of olaparib- and cisplatin-
induced DNA damage
FEN1 has been implicated in the repair of damage induced by PARP inhibitors [19, 84]. Such
inhibitors both prevent the repair of alkylated bases through inhibition of BER or the trapping
of PARP1/2 to DNA breaks. Such lesions stall replication forks and, if left unrepair, are con-
verted to DSBs following fork collapse. Disruption of the DSB recognition machinery, HR or
the FA pathways sensitise cells to PARP inhibitors, such as olaparib or veliparib [53, 79, 80,
84–88]. Since the data above suggests a synthetic lethal interaction between FEN1 inhibition
and the disruption of genes known to be required for the repair of damage induced by PARP
inhibitors, we wanted to examine whether FEN1 inhibition would have an effect on olaparib
sensitivity in cells disrupted for these pathways, particularly the FA pathway and BRCA2. Con-
sistent with previous data, we found that cells down-regulated for FEN1, FANCD2 or BRCA2
with shRNA were profoundly more sensitive to olaparib than non-target control cells (Fig 6A).
Next we examined whether treatment with 1 was able to recapitulate this sensitivity in cells
otherwise wild-type for FEN1. We found that, treatment with 10 μM 1 sensitised cells to a simi-
lar extent to FEN1 knockdown by shRNA (panel A in S5 Fig and Fig 6B). Interestingly, cells
disrupted for FEN1 by shRNA were sensitised to olaparib further by treatment with 1. This
could be a result of the inactivation of remaining FEN1, the inactivation of EXO1 or through a
dominant negative effect. To determine whether FEN1 inhibition would potentiate the toxic
effects of olaparib in BRCA2 and FANCD2 deficient cells, we pre-treated cells expressing
shRNA against either gene with 10 μM 1 before adding varying concentrations of olaparib.
While BRCA2 disrupted cells showed intermediate sensitivity to olaparib, co-treatment with 1
led to an increase in sensitivity that phenocopied a FEN1 disrupted cell-line (panel B of S5
Fig). Similarly, FANCD2 disrupted cells treated with 1 were no more sensitive to olaparib than
FANCD2 cells treated with DMSO alone (Fig 6C). These data would suggest that FEN1 is epi-
static with BRCA2 and the FA pathway for the repair of olaparib-induced DNA damage, while
it was shown above that disruption of FEN1 induces damage that requires the FA pathway for
its repair. To examine whether this epistasis was specific for olaparib or for other replication-
coupled repair, we repeated these experiments replacing olaparib with the cross-linking agent
cisplatin (CDDP). The Saccharomyces cerevisiae homologue of FEN1, Rad27, plays a role in the
repair of DNA interstrand cross-links (ICLs) in a pathway independent of the 5’-3’ exonucle-
ase Pso2 [22, 25]. Similarly, FEN1 has been implicated in the repair of cisplatin (CDDP)-
induced ICLs [8], however no formal role for FEN1 has been assigned in this pathway. We
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treated cells disrupted for FEN1 by shRNA with CDDP and compared sensitivity to cells dis-
rupted for known ICL-repair genes (FANCD2 and XPF) (Fig 6D). We found that, not only
were FEN1 disrupted cells sensitive to CDDP, this sensitivity phenocopied cells disrupted for
FANCD2 and XPF. Pre-treatment with 1, again, sensitised FEN1 proficient cells to a level
Fig 6. FEN1 is epistatic with FANCD2 for the repair of olaparib- and cisplatin-induced DNA damage. A. Olaparib sensitivity of cells disrupted for
FEN1, FANCD2 or BRCA2 by shRNA compared to a non-target control. B. Sensitisation of cells to olaparib following treatment with 10 μM 1. C. Epistasis
analysis of FEN1 inhibition and FANCD2 depletion following exposure to olaparib. D. Cisplatin sensitivity of cells disrupted for FEN1, XPF and FANCD2
by shRNA compared to a non-target control. E. Sensitisation of cells to cisplatin following treatment with 5 μM 1. F. Epistasis analysis of FEN1 inhibition
and FANCD2 depletion following exposure to cisplatin. G-I. Sensitivity of Saccharomyces cerevisiae strains deleted for rad27, pso2, msh2 singularly and
in combination either in asynchronous culture (G) or synchronised in S-phase (H-I). In all cases, each data point is the mean of at least 3 individual repeats
and the error bars represent the standard error. Significance was determined by student t-test. ns = not significant * p < 0.05. ** p < 0.005.
https://doi.org/10.1371/journal.pone.0179278.g006
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consistent with inhibition of the enzyme (Fig 6E) and was epistatic with down-regulation of
FANCD2 (Fig 6F). These data, together with the data described above, suggest a role for FEN1
in the FA pathway for the repair of replication-associated DNA damage. Since S. cerevisiae has
a prototypical FA pathway that functions in the absence of Pso2 [89–92], we wanted to exam-
ine whether this putative role for FEN1 was conserved. S. cerevisiae RAD27was deleted in a
pso2 background and the resulting strains treated with nitrogen mustard (HN2) in asynchro-
nous culture or cultures held in S-phase. Consistent with previous data [22, 25], we found that
rad27 cells were insensitive to HN2 in asynchronous culture, yet co-disruption of pso2 led to a
synergistic increase in sensitivity (Fig 6G). This phenotype persisted in cells held in S-phase
(Fig 6H) with pso2 rad27 phenocopying pso2 msh2 (Fig 6I), suggesting a conserved role for
Rad27/FEN1 in the Saccharomyces cerevisiae FA pathway. These data together hint at a role for
FEN1 in a FA-related pathway. This is somewhat consistent with previous data as FEN1 activ-
ity has been shown to be stimulated by the FA core-complex member FANCA [93], and has
been shown to be involved in replication fork processing and restart [15, 94]. Collectively, our
data suggest that FEN1 inhibition results in accumulation of DNA damage, which requires the
FA pathway for repair. This damage is most likely associated with a failure to process 5’ flaps
created during lagging-strand synthesis, leading to replication fork instability and, ultimately,
collapse into a DSB. Given that FEN1 appears to have a role in the FA pathway for the repair of
olaparib or CDDP-induced DNA damage, it is likely that FEN1 itself would be required for the
repair of damage induced by chemical inhibition of FEN1.
A model for the induction and repair of DNA damage associated with
chemical inhibition of FEN1
The data presented above shows that inhibition of FEN1 by N-hydroxyurea series inhibitors
leads to specific cell killing in cells disrupted for a number of DNA damage pathways. These
inhibitors activate the FA pathway (S4 Fig and [26]), suggesting an accumulation of aberrant
replication structures following FEN1 inhibition (Fig 7). Failure to stabilise and resolve these
structures appears to be extremely toxic as disruption of FANCD2 leads to extreme sensitivity
to FEN1 inhibition (Fig 5E). It is currently unclear what the precise nature of these aberrant
structures, however we have genetic evidence to suggest that they are generated behind the
replication fork, since disruption of error-free PRR leads to increased sensitivity to FEN1
inhibitors (Fig 5F). In yeast cells inhibited for Okazaki fragment maturation, PRR is thought to
be activated in response to the accumulation of long 5’ flaps [34], nicks [71] and abnormal sec-
ondary structures in the DNA such as hairpins [13, 73], and it is possible that these structures
are generated by FEN1 inhibitors.
BRCA2 and RAD51 are proteins with canonical roles in HR but they also play a role in the
protection of forks against degradation [63, 95]. Both proteins are required in the absence of
functional FEN1 (Fig 5G and 5H). It is possible that the role these proteins play in the toler-
ance of FEN1 inhibitors is solely in the protection of stalled replication forks, but it is equally
possible that canonical HR is activated in the absence of FEN1 [33, 40–42]. Failure to repair
replication forks leads to collapse and the generation of DSBs. These DSBs are repaired by
non-reciprocal HR, in which the broken arm of the fork is processed by MRN complex to cre-
ate a 3’overhang, which ultimately invades into the complete dsDNA to re-establish the repli-
cation fork. We and others [35] have shown that MRE11A is required in the absence of FEN1
activity (Fig 4) and here we have shown that cells with MSI that display disruption in MRN
complex show selective sensitivity to FEN1 inhibitors (Fig 3). MRE11A and ATM act in the
same pathway for the repair of DSBs (Fig 2) [96] and are both required for the repair of dam-
age induced by FEN1 inhibition (Fig 5A–5D). ATM is activated by FEN1 inhibitors [26] in an
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MRE11A dependent manner (Fig 4G) suggesting the presence of DSBs. There is, however, no
requirement for NHEJ in the repair of damage induced by FEN1 inhibitors (Fig 5H), suggest-
ing that the damage induced is not a simple two-ended DSB. MRE11A, however, also plays a
role in the processing and restart of stalled replication forks [63, 97] and it may be that the
function of MRE11A is in the processing of aberrant replication structures.
Finally, we have shown that FEN1 operates in the repair of lesions induced by cisplatin,
nitrogen mustard and olaparib in a pathway that also requires FANCD2 (Fig 6). This suggests
a role for FEN1 in replication-coupled DNA repair, which could include damage induced by
FEN1 inhibition. The role for FEN1 in the repair of these lesions is unclear, however there is
evidence to suggest that FEN1 plays a role in replication restart and the processing of stalled
replication forks [15, 16, 94, 98]. It would be interesting to determine the precise function of
FEN1 in this pathway.
The work presented here suggests that inhibitors of FEN1 would be effective in targeting
cells deleted, mutated or disrupted for a number of DNA damage response genes, many of
which are associated with cancer [99]. Similarly, FEN1 inhibitors sensitise cells to chemothera-
peutics such as cisplatin, and DNA repair inhibitors such as olaparib. The work presented here
supports FEN1 as a possible target for oncology drug discovery.
Materials and methods
High-throughput cell-killing assay
Toxicity was calculated by using a modified, high-throughput version of the MTS assay. Cells
were plated at an appropriate density in 96-well plates and allowed to adhere for 24 h. Com-
pound, diluted in DMSO, was added to a final concentration of between 0 and 30 μM and
plates were incubated at 37˚C for 0 or 2 days. Subsequently, CellTiter96 AQueous MTS (Sigma)
was added as per the manufacturers recommendations and plates were incubated at 37˚C for 2
h. Absorbance was measured using a Tecan Ultra microplate reader (Tecan Life Sciences) and
data validated and analysed as per internal data handling methodology.
Fig 7. Current model for the formation and repair of DNA damage following FEN1 inhibition. The
inhibition of FEN1 leads to the accumulation of immature Okazaki fragments bound by RPA, accumulating
aberrant replication structures that destabilise the replication fork. The PRR machinery is thought to allow for
the tolerance of such structures by switching template strand, however failure to do so in a timely manner
could lead to the stalling and, ultimately, collapse of the fork. The broken fork would require processing by
endonucleases to create a 3’ overhang able to invade into back into the dsDNA and re-start replication.
Persistent inhibition of FEN1 would ultimately lead to an overwhelming level of DNA damage and, ultimately,
cell death.
https://doi.org/10.1371/journal.pone.0179278.g007
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Cell-lines and media
HeLa, FaDu, SW-620, DLD1, HCT-116 and HCT-116 chr3 were all obtained from internal
stocks. The FaDu ATM triple knock-out cell-line was created using transcription activator-like
effector nucleases (TALEN) by AstraZeneca (Discovery Sciences, Sweden). SilenciX cell-lines
were all obtained from Tebu Bioscience and knockdown of the stated gene was confirmed
externally by qPCR. All cell-lines were grown in DMEM (Sigma Aldrich) media. SilenciX cell-
lines were maintained in DMEM media supplemented with 125 μg/mL hygromycin B to pre-
vent the loss of shRNA-expression plasmids. All cell-lines were verified in-house by short tan-
dem repeat (STR) fingerprinting and routinely tested for mycoplasma.
siRNA knockdown
siRNA-lipofectamine complexes were created using Lipofectamine RNAiMAX (Thermo
Fisher Scientific) as per the manufacturer’s instructions. All siRNAs used in this study were
Dharmacon ON-TARGETplus SMARTpools (GE Healthcare). siRNA was added at a final
concentration of 20 nM and allowed to grow for 24 hours. Cells were subsequently washed
and fresh media applied to avoid lipofectamine toxicity. For knock-down confirmation, cells
were trypsinised after 3 days in fresh media, collected and lysed in Cell Panel Lysis Buffer (5
mM Tris-HCl, 3 mM EDTA, 3 mM EGTA, 50 mM NaF, 2 mM sodium orthovanadate, 0.27 M
sucrose, 10 mM ß-glycerophosphate, 5 mM sodium pyrophosphate, and 0.5% Triton X-100)
supplemented with complete protease and phosSTOP phosphotase inhibitors (both Roche).
Examples of knock-down efficiency are shown with the figures. These cells were subsequently
used for down-stream experiments discussed below.
Mammalian colony formation assay
Cells were plated at an appropriate density and allowed to settle for>24 hours in appropriate
media. Media was supplemented with compounds (1, olaparib, cisplatin) at the stated doses
and allowed to grow until colonies of>50 cells were achieved. For combination experiments,
growth media was changed after 24 hours for media supplemented with 5 or 10 μM 1 (stated
in the Fig legend) and cells were allowed to grow for 24 hours. Subsequently, media was further
supplemented with drug at the stated dose and allowed to grow until colonies of>50 cells
were achieved. For ionising radiation experiments, cells were seeded at the stated dose and
allowed to settle for 24 hours. Media was supplemented with 5 μM 1 and allowed to grow for
24 hours. Cells were subsequently exposed to ionising radiation at the stated dose. For siRNA
knockdown toxicity experiments, cells were treated with siRNA as described above and
allowed to grow in fresh media until colonies of>50 cells were achieved.
MRN complex and MMR status determination
SW620, DLD1, HCT-116 and HCT-116 chr3 cells were trypsinised, collected and lysed in Cell
Panel Lysis Buffer with complete protease and phosphotase inhibitors. Proteins were separated
by gel electrophoresis and transferred to nitrocellulose membrane by Western blot. Mem-
branes were probed, at a concentration of 1:1000 unless stated otherwise, for ATM (sc-23921,
Santa Cruz Biotechnology), MSH2 (556349, BD Pharmigen), MLH1 (WH0004292M2, Sigma
Aldrich), MSH6 (610918, BD Transduction), MRE11A (ab214, Abcam), RAD50 (611010, BD
Transduction), NBS1 (NB100-143, Novus Biologicals), FEN1 (ab109132, Abcam) and β-Actin
(A5441, Sigma Aldrich).
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Damage induction assay
DNA damage induction was determined as described previously [26]. Briefly, cells were plated
at an appropriate density and allowed to settle overnight. Media was supplemented with 1 at
the dose stated and cells were allowed to grow for 4 days with constant exposure. Cells were
trypsinised, collected and lysed in Cell Panel Lysis Buffer with complete protease and phospho-
tase inhibitors. Proteins were separated by gel electrophoresis and transferred to nitrocellulose
membrane by Western blot. Membranes were probed, at a concentration of 1:1000 unless
stated otherwise, for γH2AX (#2577, Cell Signaling Technology; 1:500), GAPDH (#3683, Cell
Signaling Technology; 1:5000), phospho-ATM (Ser1981) (ab81292, Abcam) and FANCD2 (sc-
20022, Santa Cruz Biotechnology).
Immunofluorescence
Cells were seeded in 96-well plates at an appropriate density and allowed to settle for 24 hours.
Media was supplemented with compound at the stated dose and allowed to grow with constant
dosing for 4 days. Cells were fixed in a final concentration of 4% paraformaldehyde for 20 min
and washed 3 times in PBSA. Cells were permeablized for 4 min in 0.5% triton X-100 in PBSA,
washed and probed with anti-γH2AX (JBW301, Millipore) or anti-RAD51 (ABE257, Millipore)
at 1:500 for 48 hours at 4˚C. Cells were washed in 0.05% Tween in PBSA 3 times for 5 min before
probing for 1 hour at room temperature with AlexaFluor 488 or AlexaFlour 546-conjugated sec-
ondary antibodies (both Life Technologies) at a concentration of 1:500, and Hoechst DNA stain
at 1:2000. Immunoflourescence was examined using CellInsight CX5 (Thermo Fisher) and foci
were quantified using the software and algorithms provided to specifically count foci formed
within the nucleus. Example images of foci are shown in panels C and E of S4 Fig.
Yeast strains
Strains used in this study (S2 Table) were created as previously described [89]. Gene deletion
was carried out by micro-homology targeted gene disruption using the pFA6a vector series
and its derivatives [100–102] or generated by synthetic genetic analysis methodology [103].
Deletions were confirmed by PCR analysis and restriction enzyme digestion. Cells were grown
in YPD media and plated onto YPD agar.
Yeast nitrogen mustard sensitivity
Nitrogen mustard sensitivity was determined as previously described [25, 89]. Exponentially
growing cells were treated with increasing doses of nitrogen mustard in PBSA for 1 h at 30˚C.
Cells were washed and plated at an appropriate density and colonies were scored after 3 days
incubation at 30˚C. Percent survival is calculated as a fraction of an untreated control.
Replication-dependent nitrogen mustard sensitivity
Replication-dependent sensitivity was determined as previously described [25]. Cells were syn-
chronised in G1-phase of the cell-cycle with alpha mating factor for 2 h before being washed in
PBSA and re-suspended in fresh YPD. Cells allowed to enter S-phase for 10 min before being
treated with nitrogen mustard as described above. In pilot experiments, cell-cycle synchronisa-
tion was conducted by FACS.
Supporting information
S1 Fig. High-throughput screen for genetic backgrounds sensitive to 1. Scatter plots show
cell-line sensitivities to treatment with 1, broadly grouped by tissue of origin (A), tissue sub-
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group (B-D) or oncogene mutation status (E-G). Waterfall plot (H) shows all cell-line sensitiv-
ities to 1, with those confirmed to be MSI highlighted in green.
(TIF)
S2 Fig. High-throughput screen for genetic backgrounds sensitive to 2. Scatter plots show
cell-line sensitivities to treatment with 2, broadly grouped by tissue of origin (A), tissue sub-
group (B-D) or oncogene mutation status (E-G). Waterfall plot (H) shows all cell-line sensitiv-
ities to 2, with those confirmed to be MSI highlighted in green.
(TIF)
S3 Fig. High-throughput screen for genetic backgrounds sensitive to 3. Scatter plots show
cell-line sensitivities to treatment with 3, broadly grouped by tissue of origin (A), tissue sub-
group (B-D) or oncogene mutation status (E-G). Waterfall plot (H) shows all cell-line sensitiv-
ities to 3, with those confirmed to be MSI highlighted in green.
(TIF)
S4 Fig. A. Clonogenic survival of SW620 and HCT-116 cells treated with siRNA against
EXO1. B. Clonogeneic survival of HeLa cells disrupted for EXO1 and MRE11 following treat-
ment with 1. C. Example of γH2AX foci induced by 1 or olaparib. D. Dose dependent increase
in cells with at least 5 γH2AX foci. Data is a quantification from at least 500 cells. E. Example
of RAD51 foci induced by 1 or 3. G. Activation of the Fanconi anemia pathway in cells dis-
rupted for FEN1 compared to a non-target control.
(TIF)
S5 Fig. A. Effect treatment with 5 μM and 10 μM 1 has on sensitivity to olaparib in cells with
wild-type levels of FEN1. B. Epistasis analysis of FEN1 inhibition and BRCA2 depletion follow-
ing exposure to olaparib.
(TIF)
S6 Fig. There is no correlation between expression of FANCD2 (A), MRE11A (B), ATM (C)
or BRCA2 (D) and sensitivity to compound 1 (left), 2 (middle) or 3 (right). ρ denotes the
Pearson’s correlation coefficient.
(TIF)
S7 Fig. Original Western blots used in the construction of panel B of Fig 4.
(TIF)
S8 Fig. Original Western blots used in the construction of panel C of Fig 4.
(TIF)
S9 Fig. Original Western blots used in the construction of panel G of Fig 4.
(TIF)
S10 Fig. Original Western blots used in the construction of panel C in Fig 5.
(TIF)
S11 Fig. Original Western blots used in the construction of panel D in Fig 5.
(TIF)
S12 Fig. Original Western blots used in the construction of panel F in Fig 5.
(TIF)
S13 Fig. Original Western blots used in the construction of panel A in S4 Fig.
(TIF)
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S14 Fig. Original Western blots used in the construction of panel B in S4 Fig.
(TIF)
S15 Fig. Original Western blots used in the construction of panel F in S4 Fig.
(TIF)
S1 Table. High-throughput screen for genetic backgrounds sensitive to N-hydroxyurea
series inhibitors of FEN1 –Raw GI50 values.
(DOCX)
S2 Table. Yeast strains used in this study.  Strain kindly donated by the Boone Lab. # Strains
purchased from Open Biosystems.
(DOCX)
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